Tamiflu (Oseltamivir Phosphate) Market Is Estimated To Witness Moderate Growth Owing To Rising Demand For Antiviral Drugs

 Tamiflu (Oseltamivir Phosphate) market

Tamiflu (Oseltamivir Phosphate) is an antiviral drug used for treating and preventing influenza. It helps stop the replication of influenza viruses within the host cells so that symptoms can be relieved and risks of complications reduced. It comes as oral capsule and is administered for 5 days during seasonal flu or up to 10 days during a pandemic. The drug provides effective treatment against influenza A and B strains.

The Tamiflu (Oseltamivir Phosphate) market is estimated to be valued at US$ 464.4 Mn in 2023 and is expected to exhibit a CAGR of 3.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Tamiflu (Oseltamivir Phosphate) market is driven by the rising incidence of seasonal and pandemic influenza infections globally. According to WHO, annual epidemics result in about 1 billion cases of influenza illness worldwide. The COVID-19 pandemic has also underscored the need to strengthen prevention and control of respiratory viral infections. There is growing awareness about benefits of antiviral drugs like Tamiflu in relieving influenza symptoms faster and reducing risks of complications. The market is witnessing increase in generic formulations of Tamiflu with the patent expiration of branded Oseltamivir capsules in major markets providing affordable treatment options. However, stringent regulations for approval of generic versions and requirement of specialized manufacturing capabilities pose a challenge for new entrants in the market.

Porter’s Analysis

Threat of new entrants: The threat of new entrants into the Tamiflu market is low due to the requirement of high R&D investments and stringent regulations for drug approvals.

Bargaining power of buyers: The bargaining power of buyers is moderate as Tamiflu is available through pharmacies under prescription. However, price competition exists between several generic versions.

Bargaining power of suppliers: Tamiflu is manufactured using complex chemical synthesis processes requiring specialized equipment and facilities. This gives existing suppliers moderate bargaining power.

Threat of new substitutes: No major substitute exists for Tamiflu presently, however, researchers are exploring new antiviral drugs for influenza treatment.

Competitive rivalry: The competitive rivalry in the Tamiflu market is high due to presence of generic versions and patent expiry of Roche's brand.

SWOT Analysis

Strength: Tamiflu has strong brand recognition and is the preferred treatment for influenza. Its syrup and tablet formulations make administration easier.

Weakness: Generic versions have significantly eroded Roche's Tamiflu sales after patent expiration. Side effects like nausea and vomiting are common with Tamiflu use.

Opportunity: Increasing incidence of influenza pandemics worldwide presents an opportunity to boost Tamiflu sales. New formulations such as intravenous injections can widen its market reach.

Threats: Alternate drugs for influenza treatment and preventive vaccines pose competitive threats. Regulatory non-approvals can delay or halt new product launches.

Key Takeaways

The Global Tamiflu (Oseltamivir Phosphate) Market Size is expected to witness high growth, exhibiting CAGR of 3.1% over the forecast period, due to increasing prevalence of influenza worldwide. North America currently dominates the market owing to high demand for antiviral drugs and availability of generics. Asia Pacific is projected to be the fastest growing region between 2023-2030 with countries like India and China emerging as majorproduction and consumption hubs.

Key players operating in the Tamiflu market are Roche, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Mylan N.V., Apotex Inc., Sandoz AG, Accord Healthcare Ltd. While Roche's branded Tamiflu faces competition from generics, it continues to be the established therapy for influenza treatment globally due to its brand recognition and efficacy.

For more insights, read - https://www.dailyprbulletin.com/new-avenue-for-tamiflu-oseltamivir-phosphate-market-share


Comments

Post a Comment

Popular posts from this blog

Training Market Estimated To Witness High Growth Owing To Growing Emphasis on Developing Skillset

Image
  Training Market The Training Market Is Estimated To Be Valued At US$132.2244 Bn In 2023 And Is Expected To Exhibit A CAGR of 8.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: The training market covers products and services related to developing and enhancing skills through workshops, online programs and classroom instructions. This includes corporate training focused on technical, soft and safety skills for varied industries. The key end users are corporates, government organizations and educational institutes. Market Dynamics: The training market is expected to witness significant growth owing to growing emphasis on developing skills to cope with rising complexity and changing nature of jobs. With rapid digitalization and emerging technologies, job roles are transforming significantly necessitating continuous upskilling and reskilling of workforce. This is driving increased demand for training p...
Read more

Salmonella Testing Is Estimated To Witness High Growth Owing To Rising Food Safety Concerns

Image
Salmonella testing market The Salmonella testing market is estimated to be valued at US$ 2.91 Bn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: The Salmonella testing market involves detection and identification of Salmonella bacteria that causes food poisoning. The key products in the market are assays, kits and reagents that are used to test food samples, clinical samples and environmental samples for the presence of Salmonella. Major end-users include food processing companies, pharmaceutical companies, clinical laboratories and research institutions. Market Dynamics: Rising global outbreaks of foodborne illnesses caused by Salmonella infection is a major factor driving growth of the Salmonella testing market. According to WHO, non-typhoidal Salmonella causes over 90 million cases of gastroenteritis each year globally. Growing consumer awareness abo...
Read more

Global Lab-on-a-Chip and Microarrays (Biochip) Market Is Estimated To Witness High Growth Owing To Rising Demand for Personalized Medicine and Technological Advancements

Image
  Lab-on-a-Chip and Microarrays (Biochip) Market The Lab-on-a-Chip and Microarrays (Biochip) Market is estimated to be valued at US$ 15,268.0 Mn in 2023 and is expected to exhibit a CAGR of 13.43% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Lab-on-a-chip and microarrays (biochip) are innovative technologies that have revolutionized the field of diagnostics and drug discovery. These devices are used for sample analysis and detection of diseases at a molecular level. Lab-on-a-chip platforms offer benefits such as minimal sample requirement, high-throughput analysis, and cost-effective solutions. They find applications in various areas such as genomics, proteomics, and clinical diagnostics, among others. These biochips have the potential to provide personalized medicine by enabling rapid and accurate diagnosis, leading to effective treatments and improved patient outcomes. Market Dynamics: The market ...
Read more